Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI321 in Advanced Solid Tumors
NCT04911881Phase 1Completed
- Sponsor
- Innovent Biologics
- Start
- Jun 2021
- Primary completion
- Feb 2023
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of IBI321 in solid tumor, sponsored by Innovent Biologics. Primary endpoints: Percentage of Participants with Dose-Limiting Toxicities and Percentage of Participants with Adverse Events. Started Jun 2021; status: completed.
02
Drugs
IBI321
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04911881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04911881.